Updated Results of APHINITY at 8.4 Years Median Follow Up

Name: Updated Results of APHINITY at 8.4 Years Median Follow Up
Uploaded: 2022-11-17T15:06:00.000Z
Description: Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.

November 17, 2022

Sara M. Tolaney, MD, MPH

Video

Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.